New plenary meeting of the SECURE consortium

On 14 and 15 March 2023, the Nuclear Research and Consultancy Group welcomed all the partners of the SECURE project for the third plenary meeting at the Fallon Hotel in Alkmaar, The Netherlands.

The two intense days started with six technical workshops, focused on each of the various work packages of the project, in which the leaders of each task illustrated the progress of their activities, always allowing time and space for in-depth discussions on important themes such as the development and production strategies of irradiation targets, as well as guidelines for clinical trials and radiological safety.

In view of the upcoming reporting to the funding agency, EURATOM, there were also talks dedicated to the crucial points related to the communication and dissemination of information, as well as the management of the financial and technical aspects of the report being prepared.

The second day was dedicated to smaller individual meetings in order to discuss in detail the preparation of the deliverables that need to be submitted to the European Commission by the end of the month. After a final summary of the meeting delivered by the Coordinator Renata Mikolajczak, the consortium had the opportunity to visit the facilities of the Nuclear Research and Consultancy Group, in particular the Jaap Goedkoop Laboratory, where the development of new nuclear drugs for the treatment of patients. Also presented were the FIELD-LAB – a drug discovery facility that will help accelerate the development and market launch of new nuclear drugs for the treatment of cancer – and the future PALLAS reactor, still under construction.

For more information on the SECURE project, visit the official website.

Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Atomic Energy Community (EC-Euratom). Neither the European Union nor the granting authority can be held responsible for them.